SEC Form 4 · accession 0001562180-18-001383

Akebia Therapeutics, Inc. · AKBA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — SVP, CFO & Treasurer

Period of report

Feb 28, 2018

Accepted (ET)

Mar 2, 2018 · 4:15 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001517022

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Feb 28, 2018	A	19,500	$0.00	A	87,236	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Employee Stock Option (Right to buy)^F3	$14.30	Feb 28, 2018	A	27,700	A	—	Feb 28, 2028	Common Stock	27,700	27,700	D

F1The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan. One hundred percent of the restricted stock units will vest on the third anniversary of the grant date.
F2The total amount of beneficial securities owned includes 1,376 shares of stock purchased on June 30, 2017 at $8.92 per share and 723 shares of stock purchased on December 31, 2017 at $12.39 per share in connection with the Issuer's Employee Stock Purchase Plan.
F3The options were granted by the Issuer pursuant to its 2014 Incentive Plan. 25% of the shares underlying this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter.